A5043942519- Colorectal Cancer Treatments and Studies
- Genetic factors in colorectal cancer
- Immunotherapy and Immune Responses
- Gastric Cancer Management and Outcomes
- Hepatocellular Carcinoma Treatment and Prognosis
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Surgical Treatments
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Colorectal and Anal Carcinomas
- Colorectal Cancer Screening and Detection
- vaccines and immunoinformatics approaches
- T-cell and B-cell Immunology
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Intraperitoneal and Appendiceal Malignancies
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Cells and Metastasis
- Economic and Financial Impacts of Cancer
- Medical Imaging Techniques and Applications
- Esophageal Cancer Research and Treatment
- MRI in cancer diagnosis
University Medical Center Utrecht
2015-2025
Utrecht University
2011-2025
University of Amsterdam
2015-2024
Amsterdam University Medical Centers
2018-2024
The Netherlands Cancer Institute
2007-2023
Cancer Center Amsterdam
2015-2023
University Hospital Heidelberg
2005-2021
Heidelberg University
2005-2021
Amsterdam UMC Location University of Amsterdam
2012-2020
Radboud University Medical Center
2006-2018
Programmed death 1 (PD-1) blockade has clinical benefit in microsatellite-instability–high (MSI-H) or mismatch-repair–deficient (dMMR) tumors after previous therapy. The efficacy of PD-1 as compared with chemotherapy first-line therapy for MSI-H–dMMR advanced metastatic colorectal cancer is unknown.
As treatment options expand for metastatic colorectal cancer (mCRC), a blood marker with prognostic and predictive role could guide treatment. We tested the hypothesis that circulating tumor cells (CTCs) predict clinical outcome in patients mCRC.In prospective multicenter study, CTCs were enumerated peripheral of 430 mCRC at baseline after starting first-, second-, or third-line therapy. measured using an immunomagnetic separation technique.Patients stratified into unfavorable favorable...
Fluoropyrimidine-based chemotherapy plus the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab is standard first-line treatment for metastatic colorectal cancer. We studied effect of adding anti-epidermal receptor (EGFR) cetuximab to a combination capecitabine, oxaliplatin, and cancer.We randomly assigned 755 patients with previously untreated cancer (CB regimen, 378 patients) or same regimen weekly (CBC 377 patients). The primary end point was progression-free survival....
Purpose Panitumumab is a fully human anti–epidermal growth factor receptor (EGFR) monoclonal antibody that improves progression-free survival (PFS) in chemotherapy-refractory metastatic colorectal cancer (mCRC). This trial evaluated the efficacy and safety of panitumumab plus fluorouracil, leucovorin, irinotecan (FOLFIRI) compared with FOLFIRI alone after failure initial treatment for mCRC by tumor KRAS status. Patients Methods mCRC, one prior chemotherapy regimen Eastern Cooperative...
Noninvasive liquid biopsy analysis of circulating tumor DNA permits direct detection early-stage cancers.
Preoperative chemoradiotherapy may improve the radical resection rate for resectable or borderline pancreatic cancer, but overall benefit is unproven.In this randomized phase III trial in 16 centers, patients with cancer were randomly assigned to receive preoperative chemoradiotherapy, which consisted of 3 courses gemcitabine, second combined 15 × 2.4 Gy radiotherapy, followed by surgery and 4 adjuvant gemcitabine immediate 6 gemcitabine. The primary end point was survival intention...
In phase I/II trials, the cytotoxic T lymphocyte-associated antigen-4-blocking monoclonal antibody tremelimumab induced durable responses in a subset of patients with advanced melanoma. This III study evaluated overall survival (OS) and other safety efficacy end points melanoma treated or standard-of-care chemotherapy.Patients treatment-naive, unresectable stage IIIc IV were randomly assigned at ratio one to (15 mg/kg once every 90 days) physician's choice chemotherapy (temozolomide...
Abstract Purpose: To determine the prevalence and prognostic value of mismatch repair (MMR) status its relation to BRAF mutation (BRAFMT) in metastatic colorectal cancer (mCRC). Experimental Design: A pooled analysis four phase III studies first-line treatment mCRC (CAIRO, CAIRO2, COIN, FOCUS) was performed. Primary outcome parameter hazard ratio (HR) for median progression-free survival (PFS) overall (OS) MMR BRAF. For analysis, Cox regression performed on individual patient data. Results:...
Tumor ablation is often employed for unresectable colorectal liver metastases. However, no survival benefit has ever been demonstrated in prospective randomized studies. Here, we investigate the long-term benefits of such an aggressive approach.In this phase II trial, 119 patients with metastases (n < 10 and extrahepatic disease) received systemic treatment alone or plus local by radiofrequency ± resection. Previously, reported that primary end point (30-month overall [OS] > 38%) was met. We...
PURPOSE Preoperative chemoradiotherapy according to the for esophageal cancer followed by surgery study (CROSS) has become a standard of care patients with locally advanced resectable or junctional cancer. We aimed assess long-term outcome this regimen. METHODS From 2004 through 2008, we randomly assigned 366 either five weekly cycles carboplatin and paclitaxel concurrent radiotherapy (41.4 Gy in 23 fractions, 5 days per week) surgery, alone. Follow-up data were collected 2018. Cox...
A deficient mismatch repair system (dMMR) is present in 10–20% of patients with sporadic colorectal cancer (CRC) and associated a favourable prognosis early stage disease. Data on advanced disease are scarce. Our aim was to investigate the incidence outcome dMMR CRC. were collected from phase III study 820 CRC patients. Expression proteins examined by immunohistochemistry. In addition microsatellite instability analysis performed methylation status MLH1 promoter assessed. We then correlated...
The benefit of neoadjuvant chemoradiotherapy in resectable and borderline pancreatic cancer remains controversial. Initial results the PREOPANC trial failed to demonstrate a statistically significant overall survival (OS) benefit. long-term are reported.In this multicenter, phase III trial, patients with were randomly assigned (1:1) or upfront surgery 16 Dutch centers. Neoadjuvant consisted three cycles gemcitabine combined 36 Gy radiotherapy 15 fractions during second cycle. After...